Quantum dots as targeted doxorubicin drug delivery nanosystems

Abstract Background Lung cancer is one of the most frequently diagnosed cancers all over the world and is also one of the leading causes of cancer-related mortality. The main treatment option for small cell lung cancer, conventional chemotherapy, is characterized by a lack of specificity, resulting...

Full description

Saved in:
Bibliographic Details
Published inCancer nanotechnology Vol. 12; no. 1; pp. 1 - 27
Main Authors Monika Ruzycka-Ayoush, Patrycja Kowalik, Agata Kowalczyk, Piotr Bujak, Anna M. Nowicka, Maria Wojewodzka, Marcin Kruszewski, Ireneusz P. Grudzinski
Format Journal Article
LanguageEnglish
Published BMC 01.12.2021
Subjects
Online AccessGet full text
ISSN1868-6958
1868-6966
DOI10.1186/s12645-021-00077-9

Cover

Abstract Abstract Background Lung cancer is one of the most frequently diagnosed cancers all over the world and is also one of the leading causes of cancer-related mortality. The main treatment option for small cell lung cancer, conventional chemotherapy, is characterized by a lack of specificity, resulting in severe adverse effects. Therefore, this study aimed at developing a new targeted drug delivery (TDD) system based on Ag–In–Zn–S quantum dots (QDs). For this purpose, the QD nanocrystals were modified with 11-mercaptoundecanoic acid (MUA), L-cysteine, and lipoic acid decorated with folic acid (FA) and used as a novel TDD system for targeting doxorubicin (DOX) to folate receptors (FARs) on adenocarcinomic human alveolar basal epithelial cells (A549). NIH/3T3 cells were used as FAR-negative controls. Comprehensive physicochemical, cytotoxicity, and genotoxicity studies were performed to characterize the developed novel TDDs. Results Fourier transformation infrared spectroscopy, dynamic light scattering, and fluorescence quenching confirmed the successful attachment of FA to the QD nanocrystals and of DOX to the QD–FA nanocarriers. UV–Vis analysis helped in determining the amount of FA and DOX covalently anchored to the surface of the QD nanocrystals. Biological screening revealed that the QD–FA–DOX nanoconjugates had higher cytotoxicity in comparison to the other forms of synthesized QD samples, suggesting the cytotoxic effect of DOX liberated from the QD constructs. Contrary to the QD–MUA–FA–DOX nanoconjugates which occurred to be the most cytotoxic against A549 cells among others, no such effect was observed for NIH/3T3 cells, confirming FARs as molecular targets. In vitro scratch assay also revealed significant inhibition of A549 cell migration after treatment with QD–MUA–FA–DOX. The performed studies evidenced that at IC 50 all the nanoconjugates induced significantly more DNA breaks than that observed in nontreated cells. Overall, the QD–MUA–FA–DOX nanoconjugates showed the greatest cytotoxicity and genotoxicity, while significantly inhibiting the migratory potential of A549 cells. Conclusion QD–MUA–FA–DOX nanoconjugates can thus be considered as a potential drug delivery system for the effective treatment of adenocarcinomic human alveolar basal epithelial cells.
AbstractList Abstract Background Lung cancer is one of the most frequently diagnosed cancers all over the world and is also one of the leading causes of cancer-related mortality. The main treatment option for small cell lung cancer, conventional chemotherapy, is characterized by a lack of specificity, resulting in severe adverse effects. Therefore, this study aimed at developing a new targeted drug delivery (TDD) system based on Ag–In–Zn–S quantum dots (QDs). For this purpose, the QD nanocrystals were modified with 11-mercaptoundecanoic acid (MUA), L-cysteine, and lipoic acid decorated with folic acid (FA) and used as a novel TDD system for targeting doxorubicin (DOX) to folate receptors (FARs) on adenocarcinomic human alveolar basal epithelial cells (A549). NIH/3T3 cells were used as FAR-negative controls. Comprehensive physicochemical, cytotoxicity, and genotoxicity studies were performed to characterize the developed novel TDDs. Results Fourier transformation infrared spectroscopy, dynamic light scattering, and fluorescence quenching confirmed the successful attachment of FA to the QD nanocrystals and of DOX to the QD–FA nanocarriers. UV–Vis analysis helped in determining the amount of FA and DOX covalently anchored to the surface of the QD nanocrystals. Biological screening revealed that the QD–FA–DOX nanoconjugates had higher cytotoxicity in comparison to the other forms of synthesized QD samples, suggesting the cytotoxic effect of DOX liberated from the QD constructs. Contrary to the QD–MUA–FA–DOX nanoconjugates which occurred to be the most cytotoxic against A549 cells among others, no such effect was observed for NIH/3T3 cells, confirming FARs as molecular targets. In vitro scratch assay also revealed significant inhibition of A549 cell migration after treatment with QD–MUA–FA–DOX. The performed studies evidenced that at IC 50 all the nanoconjugates induced significantly more DNA breaks than that observed in nontreated cells. Overall, the QD–MUA–FA–DOX nanoconjugates showed the greatest cytotoxicity and genotoxicity, while significantly inhibiting the migratory potential of A549 cells. Conclusion QD–MUA–FA–DOX nanoconjugates can thus be considered as a potential drug delivery system for the effective treatment of adenocarcinomic human alveolar basal epithelial cells.
Author Piotr Bujak
Agata Kowalczyk
Ireneusz P. Grudzinski
Marcin Kruszewski
Monika Ruzycka-Ayoush
Anna M. Nowicka
Maria Wojewodzka
Patrycja Kowalik
Author_xml – sequence: 1
  fullname: Monika Ruzycka-Ayoush
  organization: Faculty of Pharmacy, Medical University of Warsaw
– sequence: 2
  fullname: Patrycja Kowalik
  organization: Faculty of Chemistry, University of Warsaw
– sequence: 3
  fullname: Agata Kowalczyk
  organization: Faculty of Chemistry, University of Warsaw
– sequence: 4
  fullname: Piotr Bujak
  organization: Faculty of Chemistry, Warsaw University of Technology
– sequence: 5
  fullname: Anna M. Nowicka
  organization: Faculty of Chemistry, University of Warsaw
– sequence: 6
  fullname: Maria Wojewodzka
  organization: Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology
– sequence: 7
  fullname: Marcin Kruszewski
  organization: Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology
– sequence: 8
  fullname: Ireneusz P. Grudzinski
  organization: Faculty of Pharmacy, Medical University of Warsaw
BookMark eNo9TttKw0AUXKSCtfYHfMoPrO4te3kRpHgpFETQ53CyZzektInsbsT-vUHFpxlmhpm5JIthHAIh15zdcG71beZCq5oywSljzBjqzshyNizVTuvFP6_tBVnnvJ9DTDrnmFuSu9cJhjIdKxxLriBXBVIXSsBZ-BrT1Pa-HypMU1dhOPSfIZ2qAYYxn3IJx3xFziMcclj_4Yq8Pz68bZ7p7uVpu7nfURS1LRQEE1aGgEoo0UYdEGrm5wfSR6kArY_Ge-41C-it5WhiC1Ya9K2WtTdyRba_vTjCvvlI_RHSqRmhb36EMXUNpNL7Q2hsHSNjXCuNURmPLYvccxVtCw7YPPkNRbBclw
ContentType Journal Article
DBID DOA
DOI 10.1186/s12645-021-00077-9
DatabaseName DOAJ Directory of Open Access Journals
DatabaseTitleList
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1868-6966
EndPage 27
ExternalDocumentID oai_doaj_org_article_85ff001646df47cdb0f1c14f8ba9a090
GroupedDBID ---
0R~
0VY
1N0
30V
4.4
408
409
40D
7X7
875
8AO
8FE
8FG
8TC
AAFWJ
AAJSJ
AAKKN
AASML
ABEEZ
ABJCF
ABUWG
ACACY
ACGFS
ACIWK
ACULB
ADBBV
ADUKV
AFGXO
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
BAPOH
BCNDV
BENPR
BFQNJ
BGLVJ
BMC
BPHCQ
BVXVI
C24
C6C
EBLON
EBS
F5P
FYUFA
GQ8
GROUPED_DOAJ
HCIFZ
HMJXF
IZIGR
KOV
L6V
M7S
O93
OK1
P9N
PIMPY
PQQKQ
PROAC
PUEGO
QOS
R9I
S27
S3B
SCM
SOJ
T13
TSV
TUS
U2A
UKHRP
WK8
Z45
~A9
ID FETCH-LOGICAL-d258t-a20283eed4242bf6eda50c9903cf34ad8cf7cc1c60edc881d7fba837dcb635c73
IEDL.DBID DOA
ISSN 1868-6958
IngestDate Wed Aug 27 01:29:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-d258t-a20283eed4242bf6eda50c9903cf34ad8cf7cc1c60edc881d7fba837dcb635c73
OpenAccessLink https://doaj.org/article/85ff001646df47cdb0f1c14f8ba9a090
PageCount 27
ParticipantIDs doaj_primary_oai_doaj_org_article_85ff001646df47cdb0f1c14f8ba9a090
PublicationCentury 2000
PublicationDate 2021-12-01
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-01
  day: 01
PublicationDecade 2020
PublicationTitle Cancer nanotechnology
PublicationYear 2021
Publisher BMC
Publisher_xml – name: BMC
SSID ssj0000399909
Score 2.4628942
Snippet Abstract Background Lung cancer is one of the most frequently diagnosed cancers all over the world and is also one of the leading causes of cancer-related...
SourceID doaj
SourceType Open Website
StartPage 1
SubjectTerms Cytotoxicity
Doxorubicin
Lung cancer cells
Nanochemistry
Quantum dots
Targeted drug delivery
Title Quantum dots as targeted doxorubicin drug delivery nanosystems
URI https://doaj.org/article/85ff001646df47cdb0f1c14f8ba9a090
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS8QwEA2iIF7ET_xccvBatmnTNLkIq7gsCyuILuytJJnEi3ZluwX9907SCuvJi6dCKKWTB3nzkpkXQm4ER00BOSQcmEm4EJAoSG1ipBHOqBxKF_Y7Zo9iMufTRbHYuOor1IR19sDdxA1l4X30gRLgeWnBpJ5Zxr00WulURbWOjw0xFddg5F0V6zuCHXwiVCF_OmakGDYM04DQmMxCU3U4w_zl2B-pZXxA9vuckI66fzkkW64-Iruz_tT7mNw-tRh_-05RQTZUN7Qr33aAA5_LVWvCexRW7SsF9xYKLb5oretl59LcnJD5-OHlfpL09x4kkBVynegskD6SF0f-NF440EVqMZ7c-pxrkNaX1jIrUgdWYsJZeqNRaII1mD7YMj8l2_WydmeElr5QqfaF8UZyhEuzDIw1TKucAYf0nNyFuKuPztqiCmbTcQAhqHoIqr8guPiPj1ySvSwAEitFrsj2etW6a-T7tRmQndFo-jwdRIi_Aa2zqss
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantum+dots+as+targeted+doxorubicin+drug+delivery+nanosystems&rft.jtitle=Cancer+nanotechnology&rft.au=Monika+Ruzycka-Ayoush&rft.au=Patrycja+Kowalik&rft.au=Agata+Kowalczyk&rft.au=Piotr+Bujak&rft.date=2021-12-01&rft.pub=BMC&rft.issn=1868-6958&rft.eissn=1868-6966&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=27&rft_id=info:doi/10.1186%2Fs12645-021-00077-9&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_85ff001646df47cdb0f1c14f8ba9a090
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1868-6958&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1868-6958&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1868-6958&client=summon